CD8-Independent Tumor Cell Recognition Is a Property of the T Cell Receptor and Not the T Cell 1

The CD8 coreceptor enhances T cell function by stabilizing the TCR/peptide/MHC complex and/or increasing T cell avidity via interactions with the intracellular kinases Lck and LAT. We previously reported a CD4+ T cell (TIL 1383I), which recognizes the tumor-associated Ag tyrosinase in the context of HLA-A2. To determine whether CD8 independent tumor cell recognition is a property of the TCR, we used retroviral transduction to express the TIL 1383I TCR in the CD8− murine lymphoma, 58 α−/β−. Immunofluorescent staining of TCR-transduced cells with human TCR Vβ subfamily-specific and mouse CD3-specific Abs confirmed surface expression of the transferred TCR and coexpression of mouse CD3. Transduced effector cells secreted significant amounts of IL-2 following Ag presentation by tyrosinase peptide-pulsed T2 cells as well as stimulation with HLA-A2+ melanoma lines compared with T2 cells alone or HLA-A2− melanoma cells. Further analysis of TCR-transduced clones demonstrated a correlation between T cell avidity and cell surface expression of the TCR. Therefore, the TIL 1383I TCR has sufficient affinity to mediate recognition of the physiologic levels of Ag expressed by tumor cells in the absence of CD8 expression.

[1]  Oreste Acuto,et al.  Analysis of tetanus toxin peptide/DR recognition by human T cell receptors reconstituted into a murine T cell hybridoma , 1993, European journal of immunology.

[2]  T. Schumacher,et al.  Immunotherapy through TCR gene transfer , 2001, Nature Immunology.

[3]  Fred H. Gage,et al.  Development of a Self-Inactivating Lentivirus Vector , 1998, Journal of Virology.

[4]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[5]  S. Rosenberg,et al.  MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. , 1999, Cancer research.

[6]  S. Rosenberg,et al.  Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. , 1999, Journal of immunology.

[7]  S. Rosenberg,et al.  Quantitation of T-cell receptor frequencies by competitive PCR: generation and evaluation of novel TCR subfamily and clone specific competitors. , 1999, Journal of immunotherapy.

[8]  P. A. Peterson,et al.  CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes , 1996, Nature.

[9]  S. Swain,et al.  Monoclonal antibody to L3T4 blocks the function of T cells specific for class 2 major histocompatibility complex antigens. , 1984, Journal of immunology.

[10]  J W Gratama,et al.  Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR , 2000, Gene Therapy.

[11]  R. J. Cohen,et al.  Kinetics and affinity of reactions between an antigen-specific T cell receptor and peptide-MHC complexes. , 1994, Immunity.

[12]  M. Merino,et al.  Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha. , 1988, Cancer research.

[13]  S. Hedrick,et al.  Structure and specificity of the T cell antigen receptor. , 1991, Seminars in immunology.

[14]  J. Strominger,et al.  Interaction between CD4 and class II MHC molecules mediates cell adhesion , 1987, Nature.

[15]  S. Rosenberg,et al.  High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. , 1999, Journal of immunology.

[16]  T. Kitamura,et al.  Functional Reconstitution of Class II MHC-Restricted T Cell Immunity Mediated by Retroviral Transfer of the αβ TCR Complex1 , 2000, The Journal of Immunology.

[17]  M. Kalos,et al.  Transfer of Specificity for Human Immunodeficiency Virus Type 1 into Primary Human T Lymphocytes by Introduction of T-Cell Receptor Genes , 2000, Journal of Virology.

[18]  D. Kranz,et al.  Cd8− T Cell Transfectants That Express a High Affinity T Cell Receptor Exhibit Enhanced Peptide-Dependent Activation , 2001, The Journal of experimental medicine.

[19]  G. Nolan,et al.  Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. , 2001, Clinical immunology.

[20]  Hans J. Stauss,et al.  Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer , 2001, Nature Immunology.

[21]  S. Rosenberg,et al.  Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. , 1991, Journal of immunology.

[22]  T. Kitamura,et al.  Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex. , 2000, Journal of immunology.

[23]  J. Sprent,et al.  T Cell Selection in the Thymus , 1988, Immunological reviews.

[24]  L. Zheng,et al.  Differential TCR signaling regulates apoptosis and immunopathology during antigen responses in vivo. , 1998, Immunity.

[25]  V. Engelhard,et al.  Self-Tolerance to the Murine Homologue of a Tyrosinase-Derived Melanoma Antigen , 2000, The Journal of experimental medicine.

[26]  P. Coulie,et al.  Tumor antigens recognized by T cells. , 1997, Immunology today.

[27]  S. Rosenberg,et al.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. , 1987, Journal of immunological methods.

[28]  J. Berzofsky,et al.  Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Michael A. Bookman,et al.  The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56 lck , 1988, Cell.

[30]  K. Sakaguchi,et al.  Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[31]  F. Marincola,et al.  Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma , 2001, Journal of immunotherapy.

[32]  R. Fisher,et al.  T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. , 1995, Science.

[33]  M. Davis,et al.  Kinetics of T-cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Y. Chien,et al.  A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. , 1996, Immunity.

[35]  D. Wiley,et al.  The class I and class II proteins of the human major histocompatibility complex , 1995 .

[36]  J. Foote,et al.  Breaking the affinity ceiling for antibodies and T cell receptors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  L. Hood,et al.  T‐Cell Receptor Repertoire in Tumor‐Infiltrating Lymphocytes. Analysis of Melanoma‐Specific Long‐Term Lines , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[38]  L. Zheng,et al.  Autocrine feedback death and the regulation of mature T lymphocyte antigen responses. , 1995, International reviews of immunology.

[39]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[40]  S. Swain.  T Cell Subsets and the Recognition of MHC Class , 1983, Immunological reviews.

[41]  A. Sette,et al.  Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.

[42]  H. Eisen,et al.  Antigen-specific T-cell receptors and their reactions with complexes formed by peptides with major histocompatibility complex proteins. , 1996, Advances in protein chemistry.

[43]  S. Jameson,et al.  T-cell-receptor affinity and thymocyte positive selection , 1996, Nature.

[44]  M. Nishimura,et al.  Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer , 1999, Pathology & Oncology Research.

[45]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[46]  D. Fremont,et al.  High- and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. , 1998, Immunity.